20029-53-2

Basic information

• Product Name: BENZENAMINE, 4-CYCLOPENTYL-
• Synonyms: BENZENAMINE, 4-CYCLOPENTYL-;4-cyclopentylbenzenaMine
• CAS NO: 20029-53-2
• Molecular Formula: C₁₁H₁₅N
• Molecular Weight: 161.24
• Mol File: 20029-53-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BENZENAMINE, 4-CYCLOPENTYL-(CAS DataBase Reference)
• NIST Chemistry Reference: BENZENAMINE, 4-CYCLOPENTYL-(20029-53-2)
• EPA Substance Registry System: BENZENAMINE, 4-CYCLOPENTYL-(20029-53-2)

Safety Data

• Hazardous Substances Data: 20029-53-2(Hazardous Substances Data)

Upstream product

• 89410-18-4 4-(cyclopentyl)-nitrobenzene 
• 118560-25-1 4-(2-cyclopenten-1-yl)aniline 
• 106-47-8 4-chloro-aniline 
• 142-29-0 cyclopentene 
• 120-92-3 cyclopentanone 
• 142-04-1 aniline hydrochloride 
• 71-43-2 benzene 
• 96-41-3 Cyclopentanol 
• 38805-71-9 1-(4-nitrophenyl)cyclopentene 
• 91132-73-9 1-cyclopentyl-2-nitrobenzene 
• 85689-77-6 1-(4-cyclopentylphenyl)ethan-1-one 
• 700-88-9 cyclopentylbenzene 
• 137-43-9 Cyclopentyl bromide 
• 80649-39-4 4-Cyclopentylacetophenone Oxime 

Downstream Products

• 101884-12-2 4,5,6,7-tetrachloro-2-(4-cyclopentyl-phenyl)-isoindoline-1,3-dione 
• 101581-77-5 1-(4-cyclopentyl-phenyl)-2,5-dimethyl-pyrrole 
• 102888-04-0 N-(4-cyclopentyl-phenyl)-N'-(4-isopentyloxy-phenyl)-thiourea 
• 113681-96-2 1-(4-cyclopentylphenyl)piperazine 
• 85603-07-2 N-(4-cyclopentylphenyl)-3-chloropropionamide 
• 85603-08-3 N-(4-cyclopentylphenyl)-4-chlorobutyramide 
• 1063656-27-8 C₁₄H₁₉ClN₂O 
• 1233531-42-4 2-bromo-4-cyclopentylaniline 
• 100450-94-0 N-(4-cyclopentyl-phenyl)-glycine hydrazide 
• 113682-05-6 4-(4-(4-cyclopentylphenyl)-1-piperazinyl)-1-(4-fluorophenyl)butan-1-one 
• 113682-03-4 1-(4-cyclopentylphenyl)-4-(2-(3,4-dimethoxyphenyl)ethyl)piperazine 
• 113682-04-5 1-(4-cyclopentylphenyl)-4-(2-(3,4-dihydroxyphenyl)ethyl)piperazine 
• 113681-98-4 1-benzyl-4-(4-cyclopentylphenyl)piperazine 
• 113682-02-3 1-(4-cyclopentylphenyl)-4-(2-phenylethyl)piperazine 

Relevant articles and documents

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using such CFTR modulators.

PYRAZOLE DERIVATIVES AS ANTI-PLATELET AND ANTI-THROMBOTIC AGENTS

This invention relates to novel compounds of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof wherein Y, R1 through R9, and X1 through X7 are as defined in the specification, pharmaceutical compositions containing said compounds useful as P2Y1 antagonists, and to methods of treating thromboembolic disorders.

Selective alkylation of βII-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents

Aryl chloroethylureas (CEUs) are potent anti-neoplastic agents alkylating specific intracellular proteins such as βII-tubulin. Recently we have identified a new subset of CEU derived from compound 36 that alkylates thioredoxin isoform 1 (Trx-1), inhibits the nuclear translocation of Trx-1, and favors the accumulation of cells in G0/G1 phase. We have evaluated the effects of various substituents and their position on the aromatic ring of a series of derivatives of 36 on (i) the anti-proliferative activity, (ii) the cell cycle progression, (iii) the nuclear translocation of Trx-1, and (iv) their covalent binding to β-tubulin. The same experiments were performed on representative CEU derivatives where the 2-chloroethyl amino moiety is replaced by either an ethyl, a 2-aminooxazolinyl or a 2-chloroacetyl group. On one hand, our results suggest that CEUs substituted on the phenyl ring at position 3 or 4 by cycloalkyl and substituted cycloalkyl or cycloalkoxy groups inhibit the nuclear translocation of Trx-1 and arrest the cell cycle progression in G0/G1. On the other hand, CEUs substituted by a fused aromatic ring, an aliphatic chain, or a fused aliphatic ring are alkylating βII-tubulin but not Trx-1. Beside the expected inactivity of the ethylurea derivatives, none of the modification to the electrophilic moiety led to cross-selectivity of the drugs toward β-tubulin but increased the anti-proliferative activity and resulted in mitigated effects on Trx-1 translocation.

Methods and compositions for treating pain

The present application relates to compounds and methods for treating pain, incontinence and other conditions.

A novel aromatic alkylation of anilines with cyclic and acyclic ketones under hydrothermal conditions

A novel aromatic ring-alkylation was achieved by condensation between aniline-HCl salts and cyclic or acyclic ketones under hydrothermal conditions.

Unprecedented hydrothermal reaction of o-phenylaniline and related derivatives with cyclic ketones. A novel approach to the construction of phenanthridine and quinoline ring systems

(Matrix presented) A new method for synthesizing phenanthridine and its related compounds was developed using the condensation of o-phenylaniline and its homologues with cyclic ketones under hydrothermal conditions.

Photochemical conversion of 4-chloroaniline into 4-alkylanilines

Irradiation of 4-chloroanilines in the presence of alkenes gives 4-(2′-chloroalkyl)-anilines. When the irradiation is carried out in the presence of NaBH4, 4-alkylanilines are obtained directly. The reaction appears to occur via the corresponding phenyl cation.

Photoinduced, ionic Meerwein arylation of olefins

Irradiation of 4-chloroaniline or of its N,N-dimethyl derivative in polar solvents generates the corresponding triplet phenyl cations. These are trapped by alkenes yielding arylated products in medium to good yields. B3LYP calculations show that the triplet cation slides with negligible activation energy to a bonded adduct with ethylene, whereas it forms only a marginally stabilized CT complex with water (chosen as a representative σ nucleophile). The structure of the final products depends on the preferred path from the adduct cation with the alkene. In the case of aryl olefins, this deprotonates to stilbene derivatives, while, from 2,3-dimethyl-2-butene and allytrimethylsilane, allylanilines are obtained by elimination of an electrofugal group in γ. In the case of mono- and disubstituted alkenes the cation adds chloride rather than eliminating and β-chloroalkylanilines are obtained. The regio- and sterochemistry of the addition across the alkene are best understood with a phenonium ion structure for the adduct. The nucleophile entering in fi can be varied under conditions in which the adduct cation is trapped more efficiently than the starting phenyl cation. Thus, β-methoxyalkylanilines are formed when the irradiation is carried out in methanol. β-Iodoalkylanilines are obtained in acetonitrile containing iodide and unsubstituted alkylanilines in the presence of sodium borohydride. A case of intramolecular nucleophilic trapping is found with 4-pentenoic acid. The reaction is a wide-scope ionic analogue of the radicalic Meerwin arylation of olefins.

Synthesis of para-cyclopentylanilines from ortho-(cyclopent-1′-enyl)anilines

ortho - para-Migration of the cyclopentenyl fragment in 2-(cyclopent-1′-enyl)aniline or 2-(cyclopent-1′-enyl)-6-methylaniline hydrochloride at 200 °C gives 4-cyclopentylaniline or 4-cyclopentyl-2-methylaniline.

Synthesis and evaluation of 4-alkylanilines as mammary tumor inhibiting aromatase inhibitors

The 4-alkylanilines 1-20 were synthesized to elucidate the importance of the glutarimide moiety for the aromatase inhibiting activity of aminoglutethimide [3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione, AG], the only non-steroidal aromatase inhibitor which is commercially available at present. The most interesting compounds were the (4-aminophenyl)cycloalkanes 4-6 (4, c-pentyl; 5, c-hexyl; 6, c-heptyl) and the 1-alkyl-1-(4-aminophenyl)cyclohexanes 1-3 (1, CH3; 2, C2H5; 3, n-C3H7). Derivatives 1-6 are stronger inhibitors of human placental aromatase than AG exhibiting relative potencies from 1.5 to 2.7 (AG≡1). For selectivity of action, the inhibition of desmolase (cholesterol side chain cleavage enzyme) was determined. Compounds 1-3 showed an inhibition comparable to AG, whereas compounds 4-6 exhibited no effect on desmolase. Being more potent and selective aromatase inhibitors in vitro, compounds 4-6, however, were not superior to AG in vivo, when the reduction of plasma estradiol concentration and the tumor inhibiting activity (PMSG-primed SD rats and DMBA-induced mammary carcinoma of the SD rat, postmenopausal model) were concerned.